Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22441066 | 1.00 | LMNA (0.38) | LMNASMN1; SMN2JAK3USP30ALDH1A1 | |
| SCHEMBL22441070 | 1.00 | LMNA (0.38) | LMNASMN1; SMN2JAK3USP30ALDH1A1 | |
| SCHEMBL17747852 | 0.87 | LMNA (0.38) | LMNASMN1; SMN2JAK3USP30ALDH1A1 | |
| SCHEMBL1356255 | 0.87 | LMNA (0.38) | LMNASMN1; SMN2JAK3USP30ALDH1A1 | |
| SCHEMBL23086759 | 0.87 | LMNA (0.38) | LMNASMN1; SMN2JAK3USP30ALDH1A1 | |
| SCHEMBL16470712 | 0.87 | LMNA (0.38) | LMNASMN1; SMN2JAK3USP30ALDH1A1 | |
| SCHEMBL22497045 | 0.82 | LMNA (0.39) | LMNASMN1; SMN2JAK3ALDH1A1 | |
| SCHEMBL1438568 | 0.82 | LMNA (0.39) | LMNASMN1; SMN2JAK3ALDH1A1 | |
| SCHEMBL1437707 | 0.79 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL652815 | 0.78 | LMNA (0.36) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961247-B2 | Pyrazolopyrimidine derivatives as kinase inhibitor | MAP3K5, MAP3K2, MAPKAPK5 | LMNA 4349/4885SMN1; SMN2 2738/4885JAK3 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.